Why the study?
Does switching to a fixed-dose losartan (50 mg)/hydrochlorothiazide (12.5 mg) combination improve blood pressure and maintain safety over 3 years in Japanese patients with hypertension uncontrolled on ARB or ACE inhibitor regimens?
Does switching to a fixed-dose losartan (50 mg)/hydrochlorothiazide (12.5 mg) combination improve blood pressure and maintain safety over 3 years in Japanese patients with hypertension uncontrolled on ARB or ACE inhibitor regimens?
Switching to a fixed-dose combination of losartan 50 mg and hydrochlorothiazide 12.5 mg safely and effectively reduces blood pressure over 3 years in Japanese patients with hypertension uncontrolled on ACEi/ARB therapy.
Concerns about metabolic complications often disturb prolonged use of diuretics in Japan. We investigated 3-year safety and efficacy in Japanese patients with hypertension who were uncontrolled with angiotensin receptor blocker or angiotensin-converting enzyme inhibitor regimens and then switched to losartan (50 mg)/hydrochlorothiazide (12.5 mg; HCTZ) combinations. Blood pressure decreased favorably and maintained a steady state for 3 years (157 ± 16/88 ± 11 mm Hg to 132 ± 13/75 ± 9 mm Hg, P < .0001). Metabolic parameters maintained a limited range of changes after 3 years, and adverse events were markedly decreased after 1-year treatment. The losartan/HCTZ combination minimized diuretic-related adverse effects and thus may be useful for the treatment of Japanese patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Kita et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: